Effect of androgens on serum lipids and lipoproteins

Solyom, Antal E.

doi:10.1007/bf02532595

Cited by 93 publications

(23 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The degree of the estrogenic influence, however, was not large despite the highly significant increases in estrogen levels (Table 3). This may be due to the actions not only of endogenous estrogens, but also of other endogenous hormones, such as progesterone and androstenedione, which are reported to have effects on lipoproteins the opposite that of estrogen (52,53). Studies examining the effects of exogenous hormones in premenopausal women, however, have found significantly higher magnitudes of change in lipid and lipoprotein levels (1).…”

Section: Discussionmentioning

confidence: 97%

Plasma Lipid and Lipoprotein Levels during the Follicular and Luteal Phases of the Menstrual Cycle

Barnett

Woods

Lamon‐Fava

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

Estrogen levels are higher during the luteal compared with the follicular phase of the menstrual cycle. It was hypothesized that the luteal compared with the follicular phase has a lipid and lipoprotein profile associated with decreased coronary heart disease (CHD) risk. This was tested using well-defined data from healthy, well-characterized premenopausal Caucasian women under very controlled metabolic conditions. The percent differences in lipid, lipoprotein, and sex hormone levels between the follicular and luteal phases were estimated using generalized estimating equations after adjusting for age, body mass index, calendar time, and season. The low-density lipoprotein cholesterol (LDL-C) level was 6.2% lower (P = 0.015), and the total cholesterol/high-density lipoprotein cholesterol (HDL-C) and LDL-C/HDL-C ratios were 5.1% (P = 0.0006) and 8.4% (P = 0.002) lower, respectively, during the luteal phase. Levels of estradiol and other estrogens were significantly higher (by>100% each; P < 0.0001 in all cases) in the luteal phase. These findings support the study hypothesis. Fluctuations in levels of LDL-C and the total cholesterol/HDL-C and LDL-C/HDL-C ratios between menstrual cycle phases need to be considered in the screening and medical monitoring of premenopausal women, especially those with borderline levels. Although small, such fluctuations may prove to be clinically significant in the long run. Studies involving premenopausal women need to more clearly define and validate menstrual cycle phase in the design and interpretation of study results.

show abstract

Section: Discussionmentioning

confidence: 97%

Plasma Lipid and Lipoprotein Levels during the Follicular and Luteal Phases of the Menstrual Cycle

Barnett

Woods

Lamon‐Fava

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

“…These findings are consis tent with the known sex difference in HDL-C and LDL-C blood levels and in the risk for cardiovascular disease. Triglyceride blood concentrations are decreased by exoge nous androgens and elevated by oral estrogens [51,52,[54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73]. These steroid effects are modified by dosage, chemical structure (synthetic steroids are more potent) and route of administration (more striking effects with oral hormones) [51.…”

Section: Discussionmentioning

confidence: 99%

Recombinant Human Growth Hormone and Oxandrolone in Treatment of Short Stature in Girls with Turner Syndrome

Stahnke¹,

Stubbe²,

Keller³

1992

Horm Res

View full text Add to dashboard Cite

91 girls with Turner syndrome (TS) with a mean chronological age (CA) and bone age (BA) of 10.3 ± 2.3 and 8.9 ± 1.9 years, respectively, were randomly assigned to subcutaneous treatment with recombinant human growth hormone (rhGH) alone (n = 47), 2.6 IU/m² body surface area daily or combination treatment (n = 44) with the same dose of rhGH and oxandrolone 0.1 mg/kg body weight orally, for the first 12 months of this study. During the 1 st year of therapy, there was a striking increase in height velocity (HV) in both groups, from 4.0 ± 0.8 to 6.3 ± 1.3 cm/year [HV standard (standards of untreated Turner patients) deviation score (SDS) for CA from 0.0 ± 0.7 to 2.9 ± 1.3] in the rhGH group and from 4.2 ± 1.2 to 8.5 ± 1.7 cm/year (HV SDS-CA from +0.3 ± 1.0 to+5.6 ± 1.6) in the combination group. The difference between the groups was statistically significant (p < 0.01). During the 2nd year of treatment, the rhGH dose was increased to 3.4 IU/m² daily for the rhGH-alone group, whereas in the combination treatment group the oxandrolone dose was reduced to 0.05 mg/kg daily. HV was maintained at significantly higher levels than those prior to treatment, at 5.3 ± 1.1 cm/year (HV SDS-CA:+2.1 ± 1.3) and 6.2 ± 1.5 cm/year (HV SDS-CA:+3.6 ± 1.4) in the rhGH-alone and the combination group, respectively (p < 0.001). After 2 years of treatment, the mean predictable adult height had increased by +3.6 ± 2.4 cm in the rhGH-alone group and by +5.3 ± 3.6 cm in the combination group. Both treatment regimens were very well tolerated although clitoral enlargement was seen in 15 of the 44 girls of the combination group who had been treated with 0.1 mg oxandrolone daily for the 1 st year. Impaired glucose tolerance was infrequently seen in girls of either group and the higher oxandrolone dose of the 1st year affected serum lipoprotein levels. Our data suggest that rhGH may improve adult height in girls with TS. This beneficial effect may be further increased by the addition of a low dose of oxandrolone (0.05 mg/kg/day).

show abstract

“…A negative relationship, however, between triglyceride concentration and testosterone level in plasma has been established [10], as has the fact that an enhanced triglyceride level is accompanied with an enhanced apolipoprotein-B concentration in plasma [25,28]. Testosterone increased the activity of LPL [6,26]. As a result of a depressed LPL activity, a lowered testosterone concentration may induce a growth in the quantity of VLDL particles whose metabolism is directly dependent on its activity [4,25].…”

Section: Discussionmentioning

confidence: 97%

“…Within this frame of reference, lipoproteins have attracted attention as °' risk factors" in the process of the origin and progress of ischaemic heart diseases. Although sex hormones, estrogens and androgens are known to affect lipid Abbreviations: HDL=high density lipoprotein; HDL-Ch= high density lipoprotein-cholesterol; LDL=low density lipoprotein; LPL=lipoprotein lipase; VLDL=very low density lipoprotein metabolism [6,26], little attention has yet been devoted to the effect of these homones on apolipoproteins. It is only recently that several studies have appeared dealing with the influence of hormones (predominantly sex hormones) on apolipoproteins [13].…”

mentioning

confidence: 99%

Concentration of Lipid, apoprotein-B and testosterone in patients with coronarographic findings

Hromadová

Hácik

Riečanský³

1985

Klin Wochenschr

View full text Add to dashboard Cite

The relationship between lipid, apolipoprotein-B and testosterone concentration and indicated coronarography was followed in male patients assigned into two age groups (under and over 50 years). Patients without a positive finding on coronary vessels served as controls. Patients of both age groups with a positive coronarographic finding showed an enhanced apolipoprotein-B and a decreased cholesterol concentration in the HDL2-high density lipoprotein subfraction. Likewise, testosterone level was also decreased in the two age groups. It appears that a lowered testosterone level may indirectly intervene into lipoprotein metabolism, or may affect the apolipoprotein-B level.

show abstract

Effect of androgens on serum lipids and lipoproteins

Cited by 93 publications

References 43 publications

Plasma Lipid and Lipoprotein Levels during the Follicular and Luteal Phases of the Menstrual Cycle

Plasma Lipid and Lipoprotein Levels during the Follicular and Luteal Phases of the Menstrual Cycle

Recombinant Human Growth Hormone and Oxandrolone in Treatment of Short Stature in Girls with Turner Syndrome

Concentration of Lipid, apoprotein-B and testosterone in patients with coronarographic findings

Contact Info

Product

Resources

About